Complete the planned spin-off of the Clinical Development business
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Jul 2022
- Due
- 31 Dec 2023
- Delivered
- 30 Jun 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Labcorp is targeting completion of the planned spin-off in the second half of 2023.”
What we found
Evidence strength A What the grades mean
Labcorp completed the spin-off of Fortrea (formerly CDCS business) on June 30, 2023, within the second half of 2023 target window.
-
A Labcorp 10-K filed 2024-02-26
“On June 30, 2023, the Company completed the previously announced separation (spin-off) of its former clinical development and commercialization services (CDCS) business, Fortrea Holdings Inc. (Fortrea).” ✓ confirmed on the page
-
A Labcorp 10-K filed 2025-02-25
“On June 30, 2023, the Company completed the previously announced separation (Spin-off) of its former clinical development and commercialization services (CDCS) business, Fortrea Holdings Inc. (Fortrea), through the Company’s pro-rata distribution of 100% of the outstanding shares of Fortrea common s” ✓ confirmed on the page
Market reaction: the shares moved -1.4% against the S&P 500 over the three sessions around the disclosure (23 Feb 2024 to 28 Feb 2024). What this measures
Checked 10 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift -184 days
- 2 versions
-
Version 1 · original · stated 28 Jul 2022
Deadline 31 Dec 2023 (“in the second half of 2023”) · wording aspirational
-
Version 2 · stated 16 Feb 2023
Deadline 30 Jun 2023 (“expected to be completed in mid-2023”) · wording expected
“the planned spin-off of its Clinical Development business, which is expected to be completed in mid-2023, subject to satisfaction of certain customary conditions.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Separation
- Indicative materiality
- Transformational rules
- Action
- Complete
- Deliverable
- Spin-off of Clinical Development business
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to customary conditions; final approval by Labcorp's Board of Directors; appropriate assurances regarding tax-free nature of separation; effectiveness of required SEC filings
- Depends on
- Regulatory, Government
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Labcorp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-LH-005734 · Corrections policy